Lyophilized Vaccine Adjuvant Emulsion for Oxidation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccine adjuvants like Compound A suffer from instability due to oxidation and poor particle size distribution in emulsion formulations, which affects their immunostimulatory activity and preservation stability.
Innovation Solution
A lyophilized emulsion formulation using squalane as an oil ingredient and ascorbate derivatives as antioxidants, along with specific surfactants and excipients, stabilizes Compound A, maintaining particle size distribution and enhancing preservation stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If squalene is used as an oil ingredient in emulsion formulation, then the formulation can be prepared, but the intramolecular unsaturated bonds of Compound A are oxidized, resulting in reduced contents of Compound A
Solution Approach 1:
The patent changes the oil ingredient from squalene to squalane, altering the chemical structure (saturated vs unsaturated) to prevent oxidation of Compound A while maintaining emulsion formulation capability
Solution Approach 2:
The patent introduces ascorbate derivatives as antioxidants to act as intermediaries that protect Compound A from oxidation, allowing the use of squalene as oil ingredient while preventing substance loss
2Ease of manufacture
If common emulsion formulation is used, then Compound A can be formulated, but the particle size distribution becomes unstable
Solution Approach 1:
The patent creates a composite formulation system combining squalane (or squalene with antioxidants), ascorbate derivatives, specific surfactants (Tween 80, Span 85), and excipients to achieve both ease of manufacture and stable particle size distribution
Solution Approach 2:
The ascorbate derivatives act as intermediaries that stabilize the emulsion system, preventing particle aggregation and maintaining stable particle size distribution while allowing straightforward formulation processes
3Reliability
If antioxidant is added to improve preservation stability, then oxidation resistance improves, but the formulation complexity increases
Solution Approach 1:
The ascorbate derivatives serve multiple functions simultaneously: they act as antioxidants to prevent Compound A degradation, stabilize particle size distribution, and maintain emulsion integrity, reducing the need for additional separate additives
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a vaccine adjuvant with improved preservation stability and immunostimulatory activity, ensuring effective antigen-specific immune reactions.
Implementation Method 1
the intramolecular unsaturated bonds of Compound A are oxidized, resulting in the reduction of contents of Compound A
Implementation Method 2
the stability to oxidation of Compound A is improved by the use of squalane as an oil ingredient
Implementation Method 3
addition of an antioxidant of ascorbate derivatives allows for the provision of a pharmaceutical formulation with a good preservation stability, in particular not only the stability to oxidation of Compound A itself but also the stability of particle size distribution
Data Source
AI summary
Provided is a composition that is useful as a vaccine adjuvant and has excellent storage stability and immunostimulatory activity. Specifically provided is a freeze-dried preparation that has high storage stability, said preparation containing a (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]benzyl}(methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosa-4,8,12,16,20,24-hexaenamide, squalane, a hydrophilic surfactant, and an oleophilic surfactant, and being characterized by containing an ascorbic acid-based antioxidant and an excipient.